Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Science Career Fair

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 8 June 2001:
Vol. 292. no. 5523, p. 1818
DOI: 10.1126/science.292.5523.1818
Prev | Table of Contents | Next

News of the Week

CANCER RESEARCH:
Transatlantic War Over BRCA1 Patent

Michael Balter

PARIS--Last week, the Institut Curie announced the discovery of a newly identified mutation in BRCA1, a human gene linked to elevated risk for breast and ovarian cancer, with a broadside against Myriad Genetics, which has developed an automated test for mutations in this gene and the related BRCA2. Because Myriad's test doesn't pick up defects like the newly identified mutation, Curie claimed, it represents "a potential danger" to French cancer patients. The attack is the opening volley in a battle over Myriad's right to market its test in Europe.

Read the Full Text

ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)